XJPX
7575
Market cap651mUSD
Oct 09, Last price
1,492.00JPY
1D
1.70%
1Q
9.46%
Jan 2017
28.01%
Name
Japan Lifeline Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Japan Lifeline Co., Ltd. is a medical technology firm based in Japan that specializes in cardiovascular healthcare devices. Its operations encompass research, manufacturing, global procurement, and sales of these specialized medical instruments within the country. The company's diverse product range includes solutions for cardiac rhythm management, such as pacemakers, implantable cardioverter defibrillators (including subcutaneous models), cardiac resynchronization therapy defibrillators and pacemakers, automated external defibrillators, and cardiopulmonary resuscitation support tools. For electrophysiology and ablation procedures, Japan Lifeline offers various electrophysiological and ablation catheters (like irrigated tip versions), endoscopic balloon ablation systems, esophageal temperature monitors, internal atrial cardioversion systems, and radio-frequency transseptal needles. Furthermore, its portfolio extends to cardiovascular and endografting products, including vascular, open, and abdominal stent-grafts. In the transvascular intervention segment, the company provides PTCA and PTA guide wires, PTCA balloon catheters, radiofrequency wires, and devices for closing atrial septal defects. Complementing these, its gastrointestinal intervention solutions encompass radiofrequency ablation systems, self-expandable colonic stents, and endoscopic guidewires. Established in 1981, Japan Lifeline Co., Ltd. maintains its headquarters in Tokyo, Japan.
Key people
Keisuke Suzuki
President, Chief Executive Officer, Representative Director · since 2005
Tatsuya Murase
Executive Vice President, Representative Director · since 2025
Takashi Ito
Managing Executive Officer, Chief Director of Cardiac Arrhythmia Business, Director · since 2026
Toshihiro Miyake
Managing Executive Officer, Senior Director of Pharmaceutical Affairs in Development Production · since 2026
Kenji Yamada
Managing Executive Officer, Chief Director of Administration, Director · since 2025
Yumiko Hoshiba
Senior Executive Officer, Director of Operation, Director · since 2025
Naohiro Nakada
Senior Executive Officer, Deputy Chief Director of Cardiac Arrhythmia Business · since 2026
Nobuo Takahashi
Senior Executive Officer, Chief Director of Global Business Development · since 2026
Hiroki Matsumura
Executive Officer, Director of EP Business in Arrhythmia Business Unit · since 2026
Masato Ichioka
Executive Officer, Director of NV Business in CVG Business Unit · since 2026
Tadatsugu Onuma
Executive Officer, Senior Director of Production in Development production Unit · since 2026
Takeyoshi Egawa
Senior Director of Business Administration, Director · since 2023
Masahiro Aoki
Director of VS Business in CVG Business Unit, Director · since 2026
Shogo Takahashi
Director · since 2022
Toru Takamiya
Senior Managing Executive Officer, Chief Director of Development Production, Director · since 2026
Yoshiaki Ikei
Independent Director · since 2017
Yutaka Karigome
Independent Director · since 2021
Naoko Kawahara
Independent Director · since 2024
Rie Nakagawa
Independent Director · since 2025
Tomonari Ooda
Independent Director · since 2025
Headquarters & legal address
東品川二丁目2番20号
東京都 品川区 140-0002
JP
東京都 品川区 140-0002
JP
Address
2-2-20, Higashishinagawa
Shinagawaku Tokyo 140-0002
JP
Shinagawaku Tokyo 140-0002
JP
Other language
Japan Lifeline Co., Ltd.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||